AHCO · NASDAQ
Average $9.18 (+50.5% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Baird | Sep 17, 2026 | Maintains | Outperform |
| UBS | Aug 6, 2026 | Maintains | Buy |
| RBC Capital | Aug 6, 2026 | Maintains | Outperform |
| Truist Securities | Aug 5, 2026 | Maintains | Buy |
| Jefferies | Jul 21, 2026 | Upgrade | Hold → Buy |
| Baird | Jul 6, 2026 | Maintains | Outperform |
| RBC Capital | May 11, 2026 | Maintains | Outperform |
| Canaccord Genuity | May 6, 2026 | Maintains | Buy |
| UBS | May 6, 2026 | Maintains | Buy |
| Truist Securities | Apr 13, 2026 | Maintains | Buy |
Updated Aug 19, 2026
AdaptHealth is well-positioned in the growing market for home medical equipment, and its differentiated, technology-driven model and wide range of products and services make it a strong player in the rapidly evolving healthcare landscape. The company's strong financials and solid organic growth, as well as its efforts towards value-based care and sustainability, make it a favorable investment option with a positive outlook for future growth.
AdaptHealth is facing challenges in its recent earnings as a result of increased labor costs, but this was necessary for the successful on-boarding of their largest capitated contract in HME history. The company is focused on investing in technology, expanding capabilities, and pursuing M&A opportunities to drive future growth. However, the company's organic earnings have not seen much growth and there are risks such as potential disruptions to operations and regulatory issues that could impact their performance.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
